AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35940087
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine infusion (0.5 mg/kg)
Trial: 34521212
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CT) or Interpersonal Psychotherapy (IPT)
Trial: 34027858
Drug: Intradermal platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal platelet-rich plasma (PRP) 1 ml
Trial: 34027858
Drug: Intradermal tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal tranexamic acid 4 mg
Trial: 36042527
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (not specified)
Trial: 32358867
Drug: SUMI+ RBCs
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUMI+ RBCs examined by immunocomplex capture fluorescence analysis (ICFA) using HIRO-305 and murine monoclonal antibodies against RBC membrane proteins carrying blood group antigens.
Trial: 35705380
Drug: Standard trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard trigger dose of hCG (5,000 or 10,000 IU)
Trial: 35221357
Drug: Prophylactic combination
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic combination of glycopyrrolate, ondansetron, and ephedrine
Trial: 35221357
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ephedrine boluses as required)
Trial: 32044091
Drug: Labelling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labelling the number of doses per package
Trial: 34503491
Drug: Fresh cassava
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh cassava root (300 mg of total substrate)
Trial: 36226669
Drug: Tapinarof 1%
RxNorm normalized name: TAPINAROF 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapinarof 1% cream
Trial: 32862716
Drug: Ticagrelor added
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor added to standard aspirin (80 mg or 100 mg)
Trial: 32862716
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to standard aspirin (80 mg or 100 mg)
Trial: 35426778
Drug: Oral arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral arginine supplementation
Trial: 34130033
Drug: High n‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High n‐3 PUFA, average n‐6 PUFA (H3) diet targeting 1500 mg EPA+DHA/day and 7% of energy from n‐6 linoleic acid (LA)
Trial: 34130033
Drug: High n‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High n‐3 PUFA, low‐n‐6 PUFA (H3L6) targeting 1500 mg EPA+DHA/day and <1.8 en% n‐6 LA
Trial: 34130033
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with typical American intakes of both EPA+DHA (<150 mg/day) and 7 en% from n‐6 LA
Trial: 35115574
Drug: IV Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Interferon (IFN) beta‐1a (10 μg) for 6 days after surgery
Trial: 33479268
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 1 mmol L-1
Trial: 33479268
Drug: Silicon (Si)
DrugBank: Silicon (DB12982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicon (Si) at 3 mmol L-1
Trial: 33479268
Drug: Cadmium (Cd)
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium (Cd) at 50 µmol L-1
Trial: 33479268
Drug: Cadmium (Cd)
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium (Cd) at 200 µmol L-1
Trial: 32769643
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (50 units, injected twice, 3 months apart)
Trial: 32769643
Drug: Placebo (injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (injected twice, 3 months apart)
Trial: 34462956
Drug: Synbiotic capsules
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic capsules (Lactobacillus, Bifidobacterium, Streptococcus, and fructooligosaccharides) twice per day for 14 days
Trial: 34610580
Drug: Paroxetine/Fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine/Fluoxetine
Trial: 35525480
Drug: BDP/FF 200/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF 200/12 μg via DPI
Trial: 35525480
Drug: BDP/FF 400/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF 400/24 μg via DPI
Trial: 35525480
Drug: BDP/FF 800/48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF 800/48 μg via DPI
Trial: 33879263
Drug: Amoxicillin (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (7-day course)
Trial: 32954807
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin (PV) in combination with bendamustine and rituximab
Trial: 34898493
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention focusing on antimicrobial agents prescribing and resistance
Trial: 34280013
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600mg over 2h (loading dose) and 1200mg over 22h (continuous group)
Trial: 33564825
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention (600 kcal energy, 20 g protein, and micronutrient supplementation daily)
Trial: 37401479
Drug: Inhaled Epoprostenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Epoprostenol (iEPO)
Trial: 33840769
Drug: Machine-based hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machine-based hand massage therapy (experimental group)
Trial: 32520602
Drug: Indirect laryngeal
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect laryngeal biopsy forceps combined with antibiotics
Trial: 32272255
Drug: Crushed prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed prasugrel tablets
Trial: 32272255
Drug: Integral prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integral prasugrel tablets
Trial: 32900785
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg once daily for 8 weeks)
Trial: 36270742
Drug: Nitisinone 10
RxNorm normalized name: nitisinone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitisinone 10 mg/day
Trial: 33636616
Drug: Seasonally adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonally adjusted 25(OH)D levels below 80 nmol/L
Trial: 32767414
Drug: Feru-guard 100M
RxNorm normalized name: Clinda-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feru-guard 100M (daily for 48 weeks)
Trial: 36991396
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplement)
Trial: 35357350
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug treatment
Trial: 35501215
Drug: 25% dextrose
RxNorm normalized name: Delflex with 4.25% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% dextrose solution
Trial: 33565409
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment (30 minutes, twice daily) on Zusanli, Tianshu, Shangjuxu, Xiajuxu, and Zhongwan, in addition to conventional western medicine for 7 days.
Trial: 33565409
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine treatment for 7 days.
Trial: 33999414
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment - participants learned of a mood-enhancing treatment and received it
Trial: 33999414
Drug: Treatment deprivation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment deprivation - participants learned of the same treatment, but did not receive it
Trial: 33999414
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - treatment was never mentioned
Trial: 36540062
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin (single dose or three consecutive days)
Trial: 36540062
Drug: FDC of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC of 400 mg albendazole and either 9‐ or 18 mg ivermectin
Trial: 36540062
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole (control)
Trial: 33822134
Drug: Epirubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin and cyclophosphamide followed by weekly paclitaxel (EC-wP)
Trial: 33822134
Drug: Epirubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin and paclitaxel followed by weekly paclitaxel (EP-wP)
Trial: 33347874
Drug: Active food
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active food preparation (making a wrap)
Trial: 33347874
Drug: Passive video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive video preparation (watching video of researcher making a wrap)
Trial: 32450917
Drug: Intravenous Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Plasma-Lyte 148 (Plasmalyte)
Trial: 34799534
Drug: Duodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duodenal infusion of capsaicin
Trial: 34640398
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg/kg (CAF-9)
Trial: 34640398
Drug: Caffeine 12
RxNorm normalized name: caffeine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 12 mg/kg (CAF-12)
Trial: 32293514
Drug: PROUD intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PROUD intervention for increasing medication treatment of opioid use disorders (OUDs)
Trial: 35063963
Drug: Levosimendan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12.5 mg single dose after induction of anaesthesia)
Trial: 35063963
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single dose after induction of anaesthesia)
Trial: 35604744
Drug: OROS‐MPH (osmotic‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS‐MPH (osmotic‐release oral system methylphenidate)
Trial: 33935094
Drug: B-vitamins (folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (folic acid 0.8 mg, vitamin B12 0.5 mg, vitamin B6 20 mg)
Trial: 35896694
Drug: QL1206 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL1206 (60 mg subcutaneously every 6 months)
Trial: 34670396
Drug: Genotype-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided therapy
Trial: 34496270
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injections (control group)
Trial: 33390325
Drug: EP0057 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP0057 (15 mg/m2 Q2W) plus paclitaxel (80 mg/m2, 3 weeks on/1 week off)
Trial: 34030873
Drug: Perioperative Low-Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perioperative Low-Dose Dexmedetomidine
Trial: 32193269
Drug: self-help control
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: self-help control treatment
Trial: 32560735
Drug: General information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General information about the correct use of complex dosage forms (Control)
Trial: 33630272
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) therapy
Trial: 34450619
Drug: Molnupiravir 300
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir 300 mg
Trial: 34450619
Drug: Molnupiravir 600
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir 600 mg
Trial: 34450619
Drug: Molnupiravir 800
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir 800 mg
Trial: 34746976
Drug: Therapist-assisted internet-delivered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-assisted internet-delivered cognitive behaviour therapy program
Trial: 32219761
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid arm, receiving two 330 mg omega-3 fatty acid capsules daily and placebo (for vitamin D3) weekly
Trial: 32219761
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two placebos (for omega-3 fatty acids) daily
Trial: 32219761
Drug: Co-supplementation arm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-supplementation arm, receiving a 50,000 IU vitamin D3 soft gel weekly and two 330 mg omega-3 fatty acids capsules daily for 8 weeks
Trial: 35715803
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine (two formulations: aluminum Alhydrogel and CAF01)
Trial: 36898233
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg/day for 1 year
Trial: 35178136
Drug: Physiotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy group (PT) received ELF EMF and LED therapy in addition to Paracetamol and NSAID-ibuprofen.
Trial: 35178136
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) received Paracetamol and NSAID-ibuprofen only.
Trial: 34162641
Drug: Internet-assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-assisted cognitive behavioural therapy (ICBT) with telephone coaching
Trial: 32108355
Drug: rhIGF-1 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-1 therapy
Trial: 32108355
Drug: Control (glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (glucocorticoid therapy only)
Trial: 35275249
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 I.U.)
Trial: 34445035
Drug: 3 g·day−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g·day−1 NZBC extract
Trial: 33346375
Drug: Olmesartan/rosuvastatin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/rosuvastatin fixed-dose combination (FDC)
Trial: 33346375
Drug: Usual regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual regimen (separate angiotensin receptor blockers and statins)
Trial: 35978350
Drug: Dengyinnaotong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengyinnaotong Capsule plus routine basic treatment
Trial: 35978350
Drug: Routine basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine basic treatment
Trial: 34376218
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker therapy (Control)
Trial: 34912120
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus trastuzumab and chemotherapy
Trial: 34339669
Drug: Patient‐controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient‐controlled intravenous analgesia with sufentanil
Trial: 34249145
Drug: Sufentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil + Lidocaine (S + L)
Trial: 34155966
Drug: Cobalt sulfate
RxNorm normalized name: cobalt sulfate
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt sulfate at 0.11 mg Co/kg dry matter (DM)
Trial: 34155966
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid at 7.2 mg/kg DM
Trial: 34155966
Drug: Cobalt sulfate
RxNorm normalized name: cobalt sulfate
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt sulfate at 0.11 mg Co/kg DM
Trial: 35999257
Drug: NewU (uniform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NewU (uniform with a new applied fabric treatment)
Trial: 33462831
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg pembrolizumab every 3 weeks
Trial: 33462831
Drug: Randomized dose
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized dose comparison studies (KN001 B2 and D)
Trial: 35641211
Drug: Ponatinib 45
RxNorm normalized name: PONATinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45 mg
Trial: 35641211
Drug: Ponatinib 30
RxNorm normalized name: PONATinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 30 mg
Trial: 35641211
Drug: Ponatinib 15
RxNorm normalized name: PONATinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 15 mg
Trial: 35641211
Drug: Ponatinib 45/15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 45/15 mg
Trial: 32716706
Drug: On-time denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: On-time denosumab dosing (within 4 weeks after the recommended date)
Trial: 32716706
Drug: Short delay
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short delay denosumab dosing (delay by 4 to 16 weeks)
Trial: 32716706
Drug: Long delay
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long delay denosumab dosing (delay by more than 16 weeks)
Trial: 38800822
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone
Trial: 38800822
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone
Trial: 35318777
Drug: Colonic gas
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic gas filling (720 mL)
Trial: 34427115
Drug: Dostarlimab (Jemperli),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dostarlimab (Jemperli), administered intravenously
Trial: 34064370
Drug: Unilateral accentuated
RxNorm normalized name: Accentrate PNV KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral accentuated eccentric loading (AEL) in the leg press exercise of the dominant leg, performed twice a week for 10 weeks.
Trial: 34848566
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous tranexamic acid over 10 min, followed by 1 g intravenous tranexamic acid over 8 hours
Trial: 32162533
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in combination with BCG
Trial: 616026381
Drug: Bimatoprost-timolol fixed
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost-timolol fixed combination (BTFC)
Trial: 35970327
Drug: ADT +
RxNorm normalized name: Antidepressant+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT + brexpiprazole 2 mg (n = 486)
Trial: 35970327
Drug: ADT +
RxNorm normalized name: Antidepressant+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT + brexpiprazole 2–3 mg (n = 770)
Trial: 34106630
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage (vibration and ring massage), once a day, 30 minutes per session, for 5 days, totaling 4 courses of treatment.